发明名称 Therapy prediction and optimization for renal failure blood therapy, especially home hemodialysis
摘要 A renal failure blood therapy system includes a renal failure blood therapy machine, a test including multiple blood samples taken at multiple times during a test therapy to determine concentration levels for each of a first solute and a second solute at each of the multiple times, and a device programmed to (i) estimate at least one first patient parameter using the determined concentration levels for the first solute, (ii) estimate at least one second patient parameter using the determined concentration levels for the second solute, (iii) determine a first plurality of acceptable treatments using the at least one first patient parameter, (iv) determine a second plurality of acceptable treatments using the at least one second patient parameter, and (v) merge the first plurality of acceptable treatments with the second plurality of acceptable treatments to determine a plurality of clinically acceptable treatments for both the first solute and the second solute.
申请公布号 US9629949(B2) 申请公布日期 2017.04.25
申请号 US201414472757 申请日期 2014.08.29
申请人 Baxter International Inc.;Baxter Healthcare SA 发明人 Akonur Alp;Leypoldt John Kenneth;Lo Ying-Cheng;Agar Baris Ugur
分类号 A61M1/16;A61M1/36;G06F19/00 主分类号 A61M1/16
代理机构 K&L Gates LLP 代理人 K&L Gates LLP
主权项 1. A renal failure blood therapy system comprising: a renal failure blood therapy machine; results from a test including multiple blood samples taken at multiple times during a test therapy, the results including concentration levels for each of a first solute and a second solute at each of the multiple times; and a device programmed to (i) estimate at least one first patient parameter using the determined concentration levels for the first solute, (ii) estimate at least one second patient parameter using the determined concentration levels for the second solute, (iii) determine a first plurality of acceptable treatments that meet a first predetermined solute clearance for the first solute using the at least one first patient parameter, (iv) determine a second plurality of acceptable treatments that meet a second predetermined solute clearance for the second solute using the at least one second patient parameter, and (v) merge the first plurality of acceptable treatments with the second plurality of acceptable treatments to determine a plurality of clinically acceptable treatments that meet the first and second predetermined solute clearances for both the first solute and the second solute.
地址 Deerfield IL US